ICLR - ICON Public Limited Company
NASDAQ
->
Healthcare
->
Diagnostics & Research
Dublin,
Ireland
Type: Equity
ICLR price evolution
ICLR
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 23 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $506.55 | $380.06 | ||
| Short term investments | $139.24 | $132.1 | ||
| Net receivables | $2942.97 | $2957.92 | $2899.31 | $2899.31 |
| Inventory | ||||
| Total current assets | $3779.01 | $3603.72 | $3411.47 | $3411.47 |
| Long term investments | $13365.15 | $13578.39 | ||
| Property, plant & equipment | $522.68 | $353.84 | $361.18 | $501.52 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $17211.11 | $16968.86 | $16989.86 | $16989.86 |
| Current liabilities | ||||
| Accounts payable | $106.17 | $83.04 | $131.58 | $131.58 |
| Deferred revenue | ||||
| Short long term debt | $29.76 | $110.15 | ||
| Total current liabilities | $2818.91 | $2742.33 | $2825.61 | $2825.61 |
| Long term debt | $3402.37 | $3408.16 | $3665.44 | $3665.44 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $7436.61 | $7383.73 | $7749.12 | $7749.12 |
| Shareholders' equity | ||||
| Retained earnings | $2866.31 | $2768.07 | $2433.72 | $2434.88 |
| Other shareholder equity | -$110.06 | -$179.56 | -$166.46 | -$143.51 |
| Total shareholder equity | $9585.13 | $9240.74 | ||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 1 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $380.06 | $290.48 | $753.92 | $840.3 |
| Short term investments | $132.1 | $137.09 | $114.32 | $1.73 |
| Net receivables | $2899.31 | $2801.49 | $2072.95 | $1207.47 |
| Inventory | $5.8 | $4.8 | ||
| Total current assets | $3411.47 | $3229.07 | $2941.2 | $2102.98 |
| Long term investments | $13578.39 | $13956.21 | $14445.89 | $20.3 |
| Property, plant & equipment | $501.52 | $504.15 | $336.44 | $258.9 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1332.63 | |||
| Total investments | ||||
| Total assets | $16989.86 | $17185.28 | $17387.09 | $3435.61 |
| Current liabilities | ||||
| Accounts payable | $131.58 | $81.19 | $90.76 | $101.55 |
| Deferred revenue | $660.88 | |||
| Short long term debt | $110.15 | $55.15 | $55.15 | |
| Total current liabilities | $2825.61 | $2690.6 | $2478.94 | $1123.94 |
| Long term debt | $3665.44 | $4599.04 | $5381.16 | $348.48 |
| Total noncurrent liabilities | $461.43 | |||
| Total debt | ||||
| Total liabilities | $7749.12 | $8687.32 | $9320.26 | $1585.37 |
| Shareholders' equity | ||||
| Retained earnings | $2434.88 | $1822.55 | $1416.08 | $1262.89 |
| Other shareholder equity | -$143.51 | -$171.54 | -$89.8 | -$34.34 |
| Total shareholder equity | $9240.74 | $8497.96 | $8066.83 | $1850.24 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 23 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2030.03 | $2066.25 | $2066.25 | |
| Cost of revenue | $1445.73 | |||
| Gross Profit | $591.41 | $620.52 | $620.52 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $195.56 | |||
| Total operating expenses | $298.12 | $1791.02 | $345.29 | |
| Operating income | $275.23 | |||
| Income from continuing operations | ||||
| EBIT | $275.23 | |||
| Income tax expense | $37.44 | -$30.16 | -$30.16 | |
| Interest expense | -$50.87 | -$79.31 | ||
| Net income | ||||
| Net income | $197.13 | $216.42 | $216.42 | |
| Income (for common shares) | $216.42 | |||
| (in millions $) | 31 Jan 2024 | 24 Feb 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8120.18 | $7741.39 | $2797.29 | |
| Cost of revenue | $5527.05 | $1977.38 | ||
| Gross Profit | $2408.03 | $2214.34 | $819.9 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $778.75 | $344.19 | ||
| Total operating expenses | $1362.31 | $6875.31 | $2387.7 | |
| Operating income | $866.08 | $409.59 | ||
| Income from continuing operations | ||||
| EBIT | $862.94 | $409.59 | ||
| Income tax expense | $11.75 | $59.41 | $47.88 | |
| Interest expense | -$331.69 | -$13.02 | ||
| Net income | ||||
| Net income | $612.34 | $505.3 | $332.33 | |
| Income (for common shares) | $505.3 | $327.81 | ||
| (in millions $) | 30 Oct 2024 | 24 Jul 2024 | 23 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $146.91 | $216.42 | ||
| Operating activities | ||||
| Depreciation | $149.63 | $149.73 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $218.59 | $440.13 | ||
| Investing activities | ||||
| Capital expenditures | -$36.29 | -$52.71 | ||
| Investments | ||||
| Total cash flows from investing | -$197.91 | -$34.2 | -$122.5 | -$226.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $2792.12 | $3263.43 | ||
| Total cash flows from financing | -$433.23 | -$71.75 | -$255.55 | -$844.04 |
| Effect of exchange rate | $0.2 | -$1 | ||
| Change in cash and equivalents | $317.4 | $506.55 | $380.06 | $89.33 |
| (in millions $) | 31 Jan 2024 | 24 Feb 2023 | 1 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $505.3 | $153.19 | $332.33 | |
| Operating activities | ||||
| Depreciation | $569.51 | $360.33 | $94.61 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $563.32 | $829.14 | $568.03 | |
| Investing activities | ||||
| Capital expenditures | -$142.16 | -$93.75 | -$51.05 | |
| Investments | $42.24 | |||
| Total cash flows from investing | -$226.65 | -$145.87 | -$6024.23 | -$46.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $4226.61 | $4568.06 | ||
| Total cash flows from financing | -$844.04 | -$864.17 | $5114.73 | -$208.33 |
| Effect of exchange rate | -$1 | $6.87 | ||
| Change in cash and equivalents | $89.33 | -$463.44 | -$88.11 | $320 |
News
Fundamentals
| Market cap | $16.77B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 82.56M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -1.22% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.84 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.34 |
| Quick ratio | N/A |